1. Plasminogen activators, tissue degradation and cancer;Dano, K.; Andreasen, P.A.; Gr0ndahl-Hansen, J.; Kristensen, K.; Nielsen, L.; Skriver, L.;Adv Cancer Res,1985
2. Directed plasminogen activation at the surface of normal and malignant cells;Pollanen, J.; Stephens, R.W.; Vaheri, A.;Adv Cancer Res,1991
3. High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia;Li, Garcia-Frade; A, Sureda; MC, Torrado; A, Garcia-Avello;Acta Haematol,1992
4. Endogenous tissue-type plasminogen activator and risk of myocardial infarction;Ridker, P.M.; Vaughan, D.E.; Stampfer, M.K.; Manson, J.E.; Hennekens, C.H.;Lancet,1993
5. Prospective study of endogenous tissue plasminogen activator and risk of stroke;Ridker, P.M.; Hennekens, C.H.; Stampfer, M.J.; Manson, J.E.; Vaughan, D.E.;Lancet,1994